Core Insights - Mapi Pharma Ltd. is participating in the 8th Annual Evercore Annual Healthcare Conference to explore partnerships for its innovative long-acting depot injectable treatments [1][2] Company Overview - Mapi Pharma is a fully integrated, late-stage clinical development biopharmaceutical company focused on developing innovative long-acting depot injectable treatments [1][7] - The company has a strong intellectual property (IP) portfolio and utilizes extended-release depot technologies for lifecycle management products across multiple therapeutic areas [3][7] Product Pipeline - Mapi's lead product, GA Depot, is under a commercialization agreement for the treatment of Relapsing Forms of Multiple Sclerosis (RMS) and is currently under FDA review following successful Phase 3 results [3][7] - The development pipeline includes an injectable version of cariprazine for schizophrenia, bipolar I, and major depression disorders, with patient enrollment in a Phase I/II study recently initiated [4][7] - Other products in development include Depot formulations for Huntington's disease, tardive dyskinesia, and hormone receptor-positive early breast cancer [6][7] Research and Development Capabilities - Mapi has a dedicated R&D team and state-of-the-art GMP approved manufacturing facility, enabling efficient development of depot products [5][7] - The company is positioned to co-develop depot drugs with partners interested in long-acting injectable lifecycle management versions of their molecules [6][7]